Abstract
Objective Functional networks derived from resting-state scalp EEG from people with idiopathic (genetic) generalized epilepsy (IGE) have been shown to have an inherent higher propensity to generate seizures than those from healthy controls when assessed using the concept of brain network ictogenicity (BNI). Herein we test whether the BNI framework is applicable to resting-state MEG and whether it may achieve higher classification accuracy relative to previous studies using EEG.
Methods The BNI framework consists in deriving a functional network from apparently normal brain activity, placing a mathematical model of ictogenicity into the network and then computing how often such network generates seizures in silico. We consider data from 26 people with juvenile myoclonic epilepsy (JME) and 26 healthy controls.
Results We find that resting-state MEG functional networks from people with JME are characterized by a higher propensity to generate seizures (i.e. BNI) than those from healthy controls. We found a classification accuracy of 73%.
Conclusions The BNI framework is applicable to MEG and capable of differentiating people with epilepsy from healthy controls. The observed classification accuracy is similar to previously achieved in scalp EEG.
Significance The BNI framework may be applied to resting-state MEG to aid in epilepsy diagnosis.
Highlights
Computational modelling is combined with MEG to differentiate people with juvenile myoclonic epilepsy from healthy controls.
Brain network ictogenicity (BNI) was found higher in people with juvenile myoclonic epilepsy relative to healthy controls.
BNI’s classification accuracy was 73%, similar to previously observed using scalp EEG.
Competing Interest Statement
JT is co-founder and Director of Neuronostics.
Funding Statement
ML gratefully acknowledges funding from Cardiff University's Wellcome Trust Institutional Strategic Support Fund (ISSF) [204824/Z/16/Z]. DK was supported by an EPSRC PhD studentship [grant number EP/N509449/1]. KH acknowledges support from the Health and Care Research Wales: Clinical Research Time Award and the Wales BRAIN Unit. JT acknowledges the financial support of the EPSRC via grant EP/N014391/2 and a Wellcome Trust Institutional Strategic Support Award (WT105618MA). JZ acknowledges the financial support of the European Research Council [grant number 716321]. KDS and KH acknowledge the support of the UK MEG MRC Partnership Grant (MRC/EPSRC, MR/K005464/1) and a Wellcome Trust Strategic Award (104943/Z/14/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All materials (functional networks) are available upon request (contact m.lopes{at}exeter.ac.uk).
